| Literature DB >> 34941392 |
Christine N Spencer1, Jennifer L McQuade2, Vancheswaran Gopalakrishnan1, John A McCulloch3, Marie Vetizou3, Alexandria P Cogdill1,4, Lorenzo Cohen5, Giorgio Trinchieri3, Carrie R Daniel6, Jennifer A Wargo1,7, Md A Wadud Khan1, Xiaotao Zhang6, Michael G White1, Christine B Peterson8, Matthew C Wong1, Golnaz Morad1, Theresa Rodgers2, Jonathan H Badger3, Beth A Helmink1, Miles C Andrews1,9, Richard R Rodrigues10, Andrey Morgun11, Young S Kim12, Jason Roszik2, Kristi L Hoffman13, Jiali Zheng6, Yifan Zhou4, Yusra B Medik4, Laura M Kahn4,14, Sarah Johnson1, Courtney W Hudgens15, Khalida Wani15, Pierre-Olivier Gaudreau16, Angela L Harris17, Mohamed A Jamal7, Erez N Baruch18, Eva Perez-Guijarro19, Chi-Ping Day19, Glenn Merlino19, Barbara Pazdrak2, Brooke S Lochmann2, Robert A Szczepaniak-Sloane1, Reetakshi Arora1, Jaime Anderson2, Chrystia M Zobniw2, Eliza Posada2, Elizabeth Sirmans2, Julie Simon1, Lauren E Haydu1, Elizabeth M Burton1, Linghua Wang7, Minghao Dang7, Karen Clise-Dwyer20,21, Sarah Schneider20, Thomas Chapman1, Nana-Ama A S Anang4, Sheila Duncan1, Joseph Toker22,23, Jared C Malke1, Isabella C Glitza2, Rodabe N Amaria2, Hussein A Tawbi2, Adi Diab2, Michael K Wong2, Sapna P Patel2, Scott E Woodman2, Michael A Davies2, Merrick I Ross1, Jeffrey E Gershenwald1, Jeffrey E Lee1, Patrick Hwu2, Vanessa Jensen24, Yardena Samuels25, Ravid Straussman25, Nadim J Ajami7, Kelly C Nelson26, Luigi Nezi27, Joseph F Petrosino13, P Andrew Futreal7, Alexander J Lazar14,7,28, Jianhua Hu29, Robert R Jenq7,30, Michael T Tetzlaff31, Yan Yan32, Wendy S Garrett33, Curtis Huttenhower32,34,35,36, Padmanee Sharma4,37,38, Stephanie S Watowich4, James P Allison4,38.
Abstract
Gut bacteria modulate the response to immune checkpoint blockade (ICB) treatment in cancer, but the effect of diet and supplements on this interaction is not well studied. We assessed fecal microbiota profiles, dietary habits, and commercially available probiotic supplement use in melanoma patients and performed parallel preclinical studies. Higher dietary fiber was associated with significantly improved progression-free survival in 128 patients on ICB, with the most pronounced benefit observed in patients with sufficient dietary fiber intake and no probiotic use. Findings were recapitulated in preclinical models, which demonstrated impaired treatment response to anti–programmed cell death 1 (anti–PD-1)–based therapy in mice receiving a low-fiber diet or probiotics, with a lower frequency of interferon-γ–positive cytotoxic T cells in the tumor microenvironment. Together, these data have clinical implications for patients receiving ICB for cancer.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34941392 PMCID： PMC8970537 DOI： 10.1126/science.aaz7015
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728